Steven Evans, PA
Medical · North Las Vegas, NVNPI 1568122000
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 30.6% of the total. 2025 is the largest year on record at $2,030, 3.1 times the $653 reported in 2022.
Across 223 payments — averaging $27.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$871
- Ardelyx, Inc.$531
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$429
- Gilead$427
- Sanofi$348
- plus $2K from 22 others
What the payments were for
- Food & beverage$6,00498%
- Education$1422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 59 | $1,880 |
| Johnson & Johnson | 45 | $871 |
| Ardelyx, Inc. | 16 | $531 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $429 |
| Gilead | 11 | $427 |
| Sanofi | 14 | $348 |
| Pfizer | 16 | $248 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $144 |
| Janssen Scientific Affairs, LLC | 1 | $138 |
| Incyte Corporation | 1 | $124 |
| Regeneron Healthcare Solutions, Inc. | 5 | $111 |
| Lilly USA, LLC | 4 | $109 |
| Intra-sana Laboratories | 2 | $100 |
| Aimmune Therapeutics, Inc. | 5 | $99 |
| Merck | 4 | $97 |
| Phathom Pharmaceuticals, Inc. | 3 | $88 |
| Celltrion USA Inc. | 4 | $85 |
| Ironwood Pharmaceuticals, Inc | 3 | $63 |
| Novo Nordisk | 2 | $41 |
| Orphalan Inc | 1 | $33 |
| Boston Scientific | 1 | $32 |
| Organon | 1 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Redhill Biopharma Inc. | 1 | $24 |
| Intercept Pharmaceuticals, Inc. | 1 | $22 |
| QOL Medical, LLC | 1 | $19 |
| Braintree Laboratories, Inc. | 1 | $13 |
| Bristol Myers Squibb | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,146 in reported general payments places this provider in the 85th percentile of 250 medical providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 85 | $65,422 |
| TrulancePlecanatide | 12 | $7,907 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 46 | $7,866 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 447 | $6,510 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 28 | $4,551 |
| CholestyramineCholestyramine (With Sugar) | 60 | $3,024 |
| Omeprazole | 347 | $2,805 |
| Dicyclomine Hcl | 158 | $2,763 |
| Lubiprostone | 23 | $2,039 |
| Lansoprazole | 123 | $1,935 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 12 | $1,757 |
| Famotidine | 237 | $1,550 |
| Sucralfate | 55 | $1,448 |
| Pantoprazole Sodium | 199 | $1,435 |
| Esomeprazole Magnesium | 39 | $708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,880 | $65,42285 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu | $429 | $9,66424 claims |
| Braintree Laboratories, Inc.Sutab | $13 | $4,55128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 medical providers in Nevada.
Other medical in North Las Vegas
- Manushak AvanesyanNorth Las Vegas$5K
- John NotabartoloLas Vegas$284K
- Rachel BowersLas Vegas$29K
- Spencer MeierLas Vegas$24K
- Megan WieselLas Vegas$19K
- Tai PhamLas Vegas$16K
- Eric HilmesLas Vegas$15K
- Wardon OjedapoLas Vegas$12K
- Melchor GochiocoLas Vegas$11K
- Ha lePahrump$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.